20 results on '"Burmeister, Bryan H."'
Search Results
2. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial.
- Author
-
Henderson, Michael A, Burmeister, Bryan H, Ainslie, Jill, Fisher, Richard, Di Iulio, Juliana, Smithers, B Mark, Hong, Angela, Shannon, Kerwin, Scolyer, Richard A, Carruthers, Scott, Coventry, Brendon J, Babington, Scott, Duprat, Joao, Hoekstra, Harald J, and Thompson, John F
- Subjects
- *
LYMPHADENECTOMY , *CANCER relapse , *LYMPH nodes , *LYMPH node surgery , *RANDOMIZED controlled trials , *CLINICAL medicine research , *RADIOTHERAPY , *COMPARATIVE studies , *SURGICAL excision , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *MELANOMA , *METASTASIS , *PROGNOSIS , *RESEARCH , *STATISTICAL sampling , *DISEASE relapse , *EVALUATION research , *KAPLAN-Meier estimator - Abstract
Background: Adjuvant radiotherapy is recommended for patients with melanoma after lymphadenectomy. We previously showed this treatment reduced risk of repeat lymph-node field cancer in patients with a high risk of recurrence but had no effect on overall survival. Here, we aim to update the relapse and survival data from that trial and assess quality of life and toxic effects.Methods: In the ANZMTG 01.02/TROG 02.01 randomised controlled trial, we enrolled patients who had undergone lymphadenectomy for a palpable lymph-node field relapse and were at high risk of recurrence at 16 hospitals (11 in Australia, three in New Zealand, one in Netherlands, and one in Brazil). We randomly assigned patients (1:1) to adjuvant radiotherapy (48 Gy in 20 fractions, given over a maximum of 30 days) or observation, stratified by institution, areas of lymph-node field (parotid and cervical, axilla, or groin), number of involved nodes (≤3 vs >3), maximum involved node diameter (≤4 cm vs >4 cm), and extent of extracapsular extension (none, limited, or extensive). Participants, those giving treatment, and those assessing outcomes were not masked to treatment allocation, but participants were unaware of each other's treatment allocation. In this follow-up, we assessed outcomes every 3 months from randomisation for the first 2 years, then every 6 months up to 5 years, then annually. The primary endpoint was lymph-node field relapse as a first relapse, assessed in patients without major eligibility infringements (determined by an independent data monitoring committee). We assessed late adverse effects (occurring >90 days after surgery or start of radiotherapy) with standard criteria in the as-treated population. This study is registered with ClinicalTrials.gov, number NCT00287196.Findings: Between March 21, 2003, and Nov 15, 2007, we randomly assigned 123 patients to adjuvant radiotherapy (109 eligible for efficacy assessments) and 127 to observation (108 eligible). The final follow-up date was Nov 15, 2011. Median follow-up was 73 months (IQR 61-91). 23 (21%) relapses occurred in the adjuvant radiotherapy group compared with 39 (36%) in the observation group (adjusted hazard ratio [HR] 0·52 [95% CI 0·31-0·88], p=0·023). Overall survival (HR 1·27 [95% CI 0·89-1·79], p=0·21) and relapse-free survival (0·89 [0·65-1·22], p=0·51) did not differ between groups. Minor, long-term toxic effects from radiotherapy (predominantly pain, and fibrosis of the skin or subcutaneous tissue) were common, and 20 (22%) of 90 patients receiving adjuvant radiotherapy developed grade 3-4 toxic effects. 18 (20%) of 90 patients had grade 3 toxic effects, mainly affecting skin (nine [10%] patients) and subcutaneous tissue (six [7%] patients). Over 5 years, a significant increase in lower limb volumes was noted after adjuvant radiotherapy (mean volume ratio 15·0%) compared with observation (7·7%; difference 7·3% [95% CI 1·5-13·1], p=0·014). No significant differences in upper limb volume were noted between groups.Interpretation: Long-term follow-up supports our previous findings. Adjuvant radiotherapy could be useful for patients for whom lymph-node field control is a major issue, but entry to an adjuvant systemic therapy trial might be a preferable first option. Alternatively, observation, reserving surgery and radiotherapy for a further recurrence, might be an acceptable strategy.Funding: National Health and Medical Research Council of Australia, Cancer Council Australia, Melanoma Institute Australia, and the Cancer Council South Australia. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
3. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial
- Author
-
Burmeister, Bryan H, Henderson, Michael A, Ainslie, Jill, Fisher, Richard, Di Iulio, Juliana, Smithers, B Mark, Hong, Angela, Shannon, Kerwin, Scolyer, Richard A, Carruthers, Scott, Coventry, Brendon J, Babington, Scott, Duprat, Joao, Hoekstra, Harald J, and Thompson, John F
- Subjects
- *
LYMPH node cancer , *LYMPH node surgery , *ADJUVANT treatment of cancer , *CANCER radiotherapy , *RETROSPECTIVE studies , *RANDOMIZED controlled trials , *HEALTH outcome assessment , *MELANOMA treatment - Abstract
Summary: Background: The use of radiotherapy after therapeutic lymphadenectomy for patients with melanoma at high risk of further lymph-node field and distant recurrence is controversial. Decisions for radiotherapy in this setting are made on the basis of retrospective, non-randomised studies. We did this randomised trial to assess the effect of adjuvant radiotherapy on lymph-node field control in patients who had undergone therapeutic lymphadenectomy for metastatic melanoma in regional lymph nodes. Methods: This randomised controlled trial included patients from 16 hospitals in Australia, New Zealand, the Netherlands, and Brazil. To be eligible for this trial, patients had to be at high risk of lymph-node field relapse, judged on the basis of number of nodes involved, extranodal spread, and maximum size of involved nodes. After lymphadenectomy, randomisation was done centrally by computer and patients assigned by telephone in a ratio of 1:1 to receive adjuvant radiotherapy of 48 Gy in 20 fractions or observation, with institution, lymph-node field, number of involved nodes, maximum node diameter, and extent of extranodal spread as minimisation factors. Participants, those giving treatment, and those assessing outcomes were not masked to treatment allocation. The primary endpoint was lymph-node field relapse (as a first relapse), analysed for all eligible patients. The study is registered at ClinicalTrials.gov, number NCT00287196. The trial is now closed and follow-up discontinued. Findings: 123 patients were randomly allocated to the adjuvant radiotherapy group and 127 to the observation group between March 20, 2002, and Sept 21, 2007. Two patients withdrew consent and 31 had a major eligibility infringement as decided by the independent data monitoring committee, resulting in 217 eligible for the primary analysis (109 in the adjuvant radiotherapy group and 108 in the observation group). Median follow-up was 40 months (IQR 27–55). Risk of lymph-node field relapse was significantly reduced in the adjuvant radiotherapy group compared with the observation group (20 relapses in the radiotherapy group vs 34 in the observation group, hazard ratio [HR] 0·56, 95% CI 0·32–0·98; p=0·041), but no differences were noted for relapse-free survival (70 vs 73 events, HR 0·91, 95% CI 0·65–1·26; p=0·56) or overall survival (59 vs 47 deaths, HR 1·37, 95% CI 0·94–2·01; p=0·12). The most common grade 3 and 4 adverse events were seroma (nine in the radiotherapy group vs 11 in the observation group), radiation dermatitis (19 in the radiotherapy group), and wound infection (three in the radiotherapy group vs seven in the observation group). Interpretation: Adjuvant radiotherapy improves lymph-node field control in patients at high risk of lymph-node field relapse after therapeutic lymphadenectomy for metastatic melanoma. Adjuvant radiotherapy should be discussed with patients at high risk of relapse after lymphadenectomy. Funding: National Health and Medical Research Council of Australia, Cancer Australia, Melanoma Institute Australia, Cancer Council of South Australia. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
4. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis
- Author
-
Sjoquist, Katrin M, Burmeister, Bryan H, Smithers, B Mark, Zalcberg, John R, Simes, R John, Barbour, Andrew, and Gebski, Val
- Subjects
- *
TREATMENT of esophageal cancer , *META-analysis , *CANCER chemotherapy , *CANCER radiotherapy , *HISTOLOGY , *CANCER-related mortality - Abstract
Summary: Background: In a previous meta-analysis, we identified a survival benefit from neoadjuvant chemotherapy or chemoradiotherapy before surgery in patients with resectable oesophageal carcinoma. We updated this meta-analysis with results from new or updated randomised trials presented in the past 3 years. We also compared the benefits of preoperative neoadjuvant chemotherapy compared with neoadjuvant chemoradiotherapy. Methods: To identify additional studies and published abstracts from major scientific meetings, we searched Medline, Embase, and Central (Cochrane clinical trials database) for studies published since January, 2006, and also manually searched for abstracts from major conferences from the same period. Only randomised studies analysed by intention to treat were included, and searches were restricted to those databases citing articles in English. We used published hazard ratios (HRs) if available or estimates from other survival data. We also investigated treatment effects by tumour histology and relations between risk (survival after surgery alone) and effect size. Findings: We included all 17 trials from the previous meta-analysis and seven further studies. 12 were randomised comparisons of neoadjuvant chemoradiotherapy versus surgery alone (n=1854), nine were randomised comparisons of neoadjuvant chemotherapy versus surgery alone (n=1981), and two compared neoadjuvant chemoradiotherapy with neoadjuvant chemotherapy (n=194) in patients with resectable oesophageal carcinoma; one factorial trial included two comparisons and was included in analyses of both neoadjuvant chemoradiotherapy (n=78) and neoadjuvant chemotherapy (n=81). The updated analysis contained 4188 patients whereas the previous publication included 2933 patients. This updated meta-analysis contains about 3500 events compared with about 2230 in the previous meta-analysis (estimated 57% increase). The HR for all-cause mortality for neoadjuvant chemoradiotherapy was 0·78 (95% CI 0·70–0·88; p<0·0001); the HR for squamous-cell carcinoma only was 0·80 (0·68–0·93; p=0·004) and for adenocarcinoma only was 0·75 (0·59–0·95; p=0·02). The HR for all-cause mortality for neoadjuvant chemotherapy was 0·87 (0·79–0·96; p=0·005); the HR for squamous-cell carcinoma only was 0·92 (0·81–1·04; p=0·18) and for adenocarcinoma only was 0·83 (0·71–0·95; p=0·01). The HR for the overall indirect comparison of all-cause mortality for neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy was 0·88 (0·76–1·01; p=0·07). Interpretation: This updated meta-analysis provides strong evidence for a survival benefit of neoadjuvant chemoradiotherapy or chemotherapy over surgery alone in patients with oesophageal carcinoma. A clear advantage of neoadjuvant chemoradiotherapy over neoadjuvant chemotherapy has not been established. These results should help inform decisions about patient management and design of future trials. Funding: Cancer Australia and the NSW Cancer Institute. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
5. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial
- Author
-
Burmeister, Bryan H., Thomas, Janine M., Burmeister, Elizabeth A., Walpole, Euan T., Harvey, Jennifer A., Thomson, Damien B., Barbour, Andrew P., Gotley, David C., and Smithers, B. Mark
- Subjects
- *
EVALUATION of clinical trials , *ESOPHAGEAL surgery , *ESOPHAGEAL tumors , *TREATMENT of drug toxicity , *ADENOCARCINOMA , *CANCER chemotherapy , *CANCER patients , *CANCER relapse , *MEDICAL needs assessment , *ONCOLOGY , *PREOPERATIVE care , *RADIOTHERAPY , *TUMOR classification , *DATA analysis , *TUMOR treatment - Abstract
Abstract: Introduction: Preoperative chemotherapy (CT) and preoperative chemoradiation therapy (CRT) for resectable oesophageal cancer have been shown to improve overall survival in meta-analyses. There are limited data comparing these preoperative therapies. We report the outcomes of a randomised phase II trial comparing preoperative CT and CRT for resectable adenocarcinoma of the oesophagus and gastro-oesophageal junction. Methods: Patients were randomised to receive preoperative CT with cisplatin (80mg/m2) and infusional 5 fluorouracil (1000mg/m2/d) on days 1 and 21, or preoperative CRT with the same drugs accompanied by concurrent radiation therapy commencing on day 21 of chemotherapy and the 5 fluorouracil reduced to 800mg/m2/d. The radiation dose was 35Gy in 15 fractions over 3weeks. The endpoints were toxicity, response rates, resection (R) status, progression-free survival (PFS), overall survival (OS) and quality of life. Results: Seventy-five patients were enroled on the study: 36 received preoperative CT and 39 preoperative CRT. Toxicity was similar for CT and CRT. Eight patients (11%) did not proceed to resection. The histopathological response rate (CRT 31% versus CT 8%, p =0.01) and R1 resection rate (CRT 0% versus CT 11%, p =0.04) favoured those receiving CRT. The median PFS was 14 and 26 months for CT and CRT respectively (p =0.37). The median OS was 29 months for CT compared with 32 months for CRT (p =0.83). Conclusions: Despite no difference in survival, the improvement from preoperative CRT with respect to margin involvement makes this treatment a reasonable option for bulky, locally advanced resectable adenocarcinoma of the oesophagus. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
6. T1-2 anal carcinoma requires elective inguinal radiation treatment – The results of Trans Tasman Radiation Oncology Group study TROG 99.02
- Author
-
Matthews, John H.L., Burmeister, Bryan H., Borg, Martin, Capp, Anne L., Joseph, David, Thompson, Kerin M., Thompson, Paul I., Harvey, Jennifer A., and Spry, Nigel A.
- Subjects
- *
CANCER radiotherapy , *ANAL cancer treatment , *CANCER chemotherapy , *FLUOROURACIL , *SURVIVAL analysis (Biometry) , *MITOMYCIN C - Abstract
Abstract: Background and purpose: Elective inguinal irradiation increases morbidity. We describe outcomes of moderate intensity chemoradiation treating anal canal and adjacent pelvic nodes only. Material and methods: Forty patients with T1-2, N0 anal carcinoma were enrolled between March 1999 and March 2003. Inguinal nodes were NOT electively irradiated. The anal canal and regional pelvic nodes received 36Gy/20# over 4weeks, and 2weeks later the anal canal was boosted with 14.4Gy/8#. Chemotherapy was 5 fluorouracil 800mg/m2/day on days 1–4 and 36–39, and Mitomycin C 10mg/m2 on day 1. Results: Median follow-up was 44months. Complete response was 95%. Four year results were; overall survival 71%, local control 82%, and colostomy-free survival (including salvage) 85%. Inguinal failure occurred in 22.5% but was isolated in only 12.5%. Treatment was well tolerated acutely with no toxic deaths. Severe late toxicity occurred in 7.5%. Conclusions: This moderate dose ‘non inguinal’ chemoradiation regimen resulted in modest acute toxicity, minimal long term morbidity and local control in line with other series. However staging failed to identify 12.5% of patients whose isolated inguinal failure might have been prevented by elective irradiation. Without more effective staging, all patients should receive elective inguinal irradiation. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
7. A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma–Trans Tasman Radiation Oncology Group (TROG) Study 96.06
- Author
-
Burmeister, Bryan H., Mark Smithers, B., Burmeister, Elizabeth, Baumann, Kathryn, Davis, Sidney, Krawitz, Hedley, Johnson, Carol, and Spry, Nigel
- Subjects
- *
MELANOMA , *RADIOTHERAPY , *NEUROENDOCRINE tumors , *LYMPH nodes - Abstract
Abstract: Background: The role of adjuvant postoperative therapy after resection of localised malignant melanoma involving regional lymph nodes remains controversial. There are no randomised trials that confirm that postoperative radiation conveys a benefit in terms of regional control or survival. Methods: Two hundred and thirty-four patients with melanoma involving lymph nodes were registered on a prospective study to evaluate the effect of postoperative radiation therapy. The regimen consisted of 48Gy in 20 fractions to the nodal basin using recommended treatment guidelines for each of the major node sites. The primary endpoints were regional in-field relapse and late toxicity. Secondary endpoints were adjacent relapse, distant relapse, overall survival, progression-free survival and time to in-field progression. Results: Adjuvant radiation therapy was well tolerated by all of the patients. As the first site of relapse, regional in-field relapses occurred in 16/234 patients (6.8%). The overall survival was 36% at 5 years. The progression-free survival and regional control rates were 27% and 91%, respectively, at 5 years. Patients with more than 2 nodes involved had a significantly worse outcome in terms of distant relapse, overall and progression-free survival. Conclusion: We believe that adjuvant radiation therapy following nodal surgery could offer a possible benefit in terms of regional control. These results require confirmation in a randomised trial. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
8. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial
- Author
-
Burmeister, Bryan H, Smithers, B Mark, Gebski, Val, Fitzgerald, Lara, Simes, R John, Devitt, Peter, Ackland, Stephen, Gotley, David C, Joseph, David, Millar, Jeremy, North, John, Walpole, Euan T, and Denham, James W
- Subjects
- *
ESOPHAGEAL cancer , *SURGICAL excision , *CANCER treatment , *OPERATIVE surgery , *CISPLATIN , *DRUG therapy - Abstract
Summary: Background: Resection remains the best treatment for carcinoma of the oesophagus in terms of local control, but local recurrence and distant metastasis remain an issue after surgery. We aimed to assess whether a short preoperative chemoradiotherapy regimen improves outcomes for patients with resectable oesophageal cancer. Methods: 128 patients were randomly assigned to surgery alone and 128 patients to surgery after 80 mg/m2 cisplatin on day 1, 800 mg/m2 fluorouracil on days 1–4, with concurrent radiotherapy of 35 Gy given in 15 fractions. The primary endpoint was progression-free survival. Secondary endpoints were overall survival, tumour response, toxic effects, patterns of failure, and quality of life. Analysis was done by intention to treat. Findings: Neither progression-free survival nor overall survival differed between groups (hazard ratio [HR] 0·82 [95% CI 0·61–1·10] and 0·89 [0·67–1·19], respectively). The chemoradiotherapy-and-surgery group had more complete resections with clear margins than did the surgery-alone group (103 of 128 [80%] vs 76 of 128 [59%], p=0·0002), and had fewer positive lymph nodes (44 of 103 [43%] vs 69 of 103 [67%], p=0·003). Subgroup analysis showed that patients with squamous-cell tumours had better progression-free survival with chemoradiotherapy than did those with non-squamous tumours (HR 0·47 [0·25–0·86] vs 1·02 [0·72–1·44]). However, the trial was underpowered to determine the real magnitude of benefit in this subgroup. Interpretation: Preoperative chemoradiotherapy with cisplatin and fluorouracil does not significantly improve progression-free or overall survival for patients with resectable oesophageal cancer compared with surgery alone. However, further assessment is warranted of the role of chemoradiotherapy in patients with squamous-cell tumours. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
9. Second primary oesophageal cancer following radiation for breast cancer
- Author
-
Matheson, J. Bronwyn, Burmeister, Bryan H., Smithers, B. Mark, Gotley, David, Harvey, Jennifer A., and Doyle, Lisa
- Subjects
- *
BREAST cancer , *TUMORS , *ESOPHAGEAL cancer - Abstract
The management of 12 women who presented with a second primary oesophageal cancer following radiotherapy for breast cancer was reviewed. It was concluded that nine cases fitted the classical description of a radiation-induced malignancy. Most cases were successfully managed with combined modality therapy in spite of their previous radiotherapy. [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
10. Targeted therapy and chemoradiotherapy in oesophageal cancer.
- Author
-
Burmeister, Bryan H and Porceddu, Sandro V
- Published
- 2013
- Full Text
- View/download PDF
11. Neoadjuvant chemoradiotherapy in resectable oesophageal cancer – Authors' reply
- Author
-
Burmeister, Bryan H and Smithers, B Mark
- Published
- 2005
- Full Text
- View/download PDF
12. The complex relationship between lung tumor volume and survival in patients with non-small cell lung cancer treated by definitive radiotherapy: A prospective, observational prognostic factor study of the Trans-Tasman Radiation Oncology Group (TROG 99.05).
- Author
-
Ball, David L., Fisher, Richard J., Burmeister, Bryan H., Poulsen, Michael G., Graham, Peter H., Penniment, Michael G., Vinod, Shalini K., Krawitz, Hedley E., Joseph, David J., Wheeler, Greg C., and McClure, Bev E.
- Subjects
- *
LUNG tumors , *LUNG cancer treatment , *CANCER radiotherapy , *LONGITUDINAL method , *SCIENTIFIC observation , *LUNG cancer patients - Abstract
Abstract: Background and purpose: To investigate the hypothesis that primary tumor volume is prognostic independent of T and N stages in patients with non-small cell lung cancer (NSCLC) treated by definitive radiotherapy. Materials and methods: Multicenter prospective observational study. Patient eligibility: pathologically proven stage I–III non-small cell lung cancer planned for definitive radiotherapy (minimum 50Gy in 20 fractions) using CT-based contouring. Volumes of the primary tumor and enlarged nodes were measured according to a standardized protocol. Survival was adjusted for the effect of T and N stage. Results: There were 509 eligible patients. Five-year survival rates for tumor volume grouped by quartiles were, for increasing tumor volume, 22%, 14%, 15% and 21%. Larger primary tumor volume was associated with shorter survival (HR=1.060 (per doubling); 95% CI 1.01–1.12; P =0.029). However, after adjusting for the effects of T and N stage, there was no evidence for an association (HR=1.029, 95% CI, 0.96–1.10, P =0.39). There was evidence, however, that larger primary tumor volume was associated with an increased risk of dying, independently of T and N stage, in the first 18months but not beyond. Conclusions: In patients treated by non-surgical means we were unable to show that lung tumor volume, overall, provides additional prognostic information beyond the T and N stage (TNM, 6th edition). There is evidence, however, that larger primary tumor volume adversely affects outcome only within the first 18months. Larger tumor size alone should not by itself exclude patients from curative (chemo)radiotherapy. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
13. Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer
- Author
-
Pryor, David I., Porceddu, Sandro V., Burmeister, Bryan H., Guminski, Alex, Thomson, Damien B., Shepherdson, Kristine, and Poulsen, Michael
- Subjects
- *
DRUG toxicity , *CETUXIMAB , *CANCER radiotherapy , *HEAD & neck cancer treatment , *SQUAMOUS cell carcinoma , *DRUG dosage - Abstract
Abstract: Purpose: To report toxicity data from the first 13 consecutive patients with locally advanced head and neck squamous cell carcinoma (LAHNSCC), ineligible for cisplatin, treated with concurrent cetuximab and radiotherapy (RT) at our institution. Materials and methods: Data were collected prospectively between August 2007 and May 2008. Planned treatment consisted of a cetuximab loading dose (400mg/m2) via intravenous infusion 1 week prior and then weekly (250mg/m2) with 70Gy in 35 daily fractions over 7 weeks. Results: Median age was 68 years (range 52–82 years). The predominant primary sites were hypopharyngeal (5) and oropharyngeal (5). Ineligibility for cisplatin consisted of renal impairment (5), hearing impairment (4) and of other major co-morbidities (4). Of the 13 patients, 10 (77%) had grade 3/4 skin reactions and 10 (77%) grade 3/4 mucositis. Six (46%) patients required admission for management of severe skin reactions and/or mucositis with 4 (31%) requiring a treatment break, median 10 days (9-15days). Only 4 (31%) patients managed to complete the planned 8 cycles of cetuximab. Of the 9 patients with 12-week post-therapy data, 7 (78%) achieved a complete response. Conclusions: Our early experience with cetuximab/RT has demonstrated a higher rate of toxicity compared with the recently reported randomised trial, resulting in low treatment compliance and delays in completing RT. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
14. Hypofractionated radiotherapy for the palliation of advanced head and neck cancer in patients unsuitable for curative treatment – “Hypo Trial”
- Author
-
Porceddu, Sandro V., Rosser, Brenda, Burmeister, Bryan H., Jones, Mark, Hickey, Brigid, Baumann, Kacy, Gogna, Kumar, Pullar, Andrew, Poulsen, Michael, and Holt, Tanya
- Subjects
- *
HEAD & neck cancer , *BRAIN tumors , *RADIOTHERAPY , *ONCOLOGY - Abstract
Abstract: Background and purpose: The primary purpose of the trial was to assess rate of tumour response to a hypofractionated course of radiotherapy in patients with incurable squamous cell carcinoma of the head and neck (HNSCC). Secondary objectives included radiation toxicity, symptom control, quality of life (QoL) and progression-free and overall survival. Patients and methods: Patients were planned to receive 30Gy in 5 fractions at 2/week, at least 3 days apart, with an additional boost of 6Gy for small volume disease (⩽3cm) in suitable patients. Thirty-seven patients were enrolled between August 2004 and March 2006. Median age was 68 (43–87) years, 81% were male and the predominant primary site was oropharynx (32%). The majority (73%) presented with Stage III–IV disease. Results: Thirty-five patients received radiotherapy, 1 died prior to treatment and one refused treatment. Of the 35 patients receiving radiotherapy, 31 (88%) received ⩾30Gy. Of the 35 patients who received treatment the overall objective response was 80%. Grade 3 mucositis and dysphagia were experienced in 9/35 (26%) and 4/35 (11%), respectively. QoL and symptom control were assessable in 21 patients. Thirteen (62%) reported an overall improvement in QoL and 14 (67%) experienced an improvement in pain. The median time to progression and death was 3.9 and 6.1 months, respectively. Conclusion: The “Hypo Trial” regimen provided effective palliative treatment in HNSCC unsuitable for curative treatment. Compliance was excellent and resulted in high response rates, symptom control and improvement in QoL with acceptable toxicity. However, progression free and overall survival was short. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
15. Whole brain irradiation following surgery or radiosurgery for solitary brain metastases: Mature results of a prematurely closed randomized Trans-Tasman Radiation Oncology Group trial (TROG 98.05)
- Author
-
Roos, Daniel E., Wirth, Andrew, Burmeister, Bryan H., Spry, Nigel A., Drummond, Katharine J., Beresford, Jennifer A., and McClure, Beverley E.
- Subjects
- *
RADIOSURGERY , *NEUROSURGERY , *RADIOTHERAPY , *METASTASIS - Abstract
Abstract: We evaluated the effect of adjuvant whole brain irradiation (WBI) after surgery or radiosurgery for solitary brain metastases in a Phase III multicentre trial with randomization to 30-36 Gy WBI or observation. The study was closed early due to slow accrual after 19 patients (WBI 10, observation 9). There was no difference in CNS failure-free survival or overall survival between the arms. There was a trend to reduced CNS relapse with WBI (30% versus 78%, P =0.12). Limited analysis of quality of life and neurocognitive function data revealed no evidence of difference between the arms. Our results are not inconsistent with two larger randomized trials and support the use of upfront WBI to decrease brain recurrence in this setting. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
16. Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery for carcinoma of the oesophagus or the gastro-oesophageal junction.
- Author
-
Faron, Matthieu, Cheugoua-Zanetsie, Armel Maurice, Thirion, Pierre, Nankivell, Matthew, Winter, Kathryn, Cunningham, David, Van der Gaast, Ate, Law, Simon, Langley, Ruth, de Vathaire, Florent, Valmasoni, Michele, Mauer, Muriel, Roth, Jack, Gebski, Val, Burmeister, Bryan H., Paoletti, Xavier, van Sandick, Johanna, Fu, Jianhua, Ducreux, Michel, and Blanchard, Pierre
- Subjects
- *
RELATIVE medical risk , *CONFIDENCE intervals , *META-analysis , *CANCER chemotherapy , *SYSTEMATIC reviews , *DESCRIPTIVE statistics , *COMBINED modality therapy , *ODDS ratio , *SQUAMOUS cell carcinoma , *ESOPHAGEAL cancer , *ESOPHAGEAL tumors , *CLINICAL trial registries - Abstract
Which neoadjuvant treatment for locally advanced thoracic oesophagus (TE) or gastro-oesophageal junction carcinoma is best remains an open question. Randomised controlled trials variously accrued patients with adenocarcinoma and squamous cell carcinoma, making strong conclusions hard to obtain. The primary objective of this individual participant data meta-analysis was to investigate the effect of neoadjuvant chemotherapy on overall survival (OS). Eligible trials should have closed to accrual before 2016 and compared neoadjuvant chemotherapy and surgery (CS) to surgery alone. All relevant published and unpublished trials were identified via searches of electronic databases, conference proceedings and clinical trial registers. The main end-point was OS. Investigators were contacted to obtain the individual patient data, which was recorded, harmonised and checked. A random-effects Cox model, stratified by trial, was used for meta-analysis and subgroup analyses were preplanned. 16 trials were identified as eligible. Individual patient data were obtained from 12 trial and 2478 patients. CS was associated with an improved OS versus surgery, hazard ratio (HR) = 0.83 [0.72–0.96], p < 0.0001, translating to an absolute benefit of 5.7% at 5-years from 16.8% to 22.5%. Treatment effects did not vary substantially between adenocarcinoma (HR = 0.73 [0.62–0.87]) and squamous cell carcinoma (HR = 0.91 [0.76–1.08], interaction p = 0.26). A somewhat more pronounced effect was observed in gastro-oesophageal junction (HR = 0.68 [0.50–0.93]) versus TE (HR = 0.87 [0.75–1.00], interaction p = 0.07). CS was also associated with a greater disease-free survival (HR = 0.74 [0.64–0.85], p < 0.001). Neoadjuvant chemotherapy conferred a better OS than surgery alone and should be considered in all anatomical location and histological subtypes. • Preoperative chemotherapy leads to better overall survival. • Disease-free survival was better too. • No differences were seen between squamous cell carcinoma and adenocarcinoma. • Greater effect for tumour located in the gastro-oesophageal junction. • No differences in postoperative morbidity or mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
17. Long-term results of positron emission tomography-directed management of the neck in node-positive head and neck cancer after organ preservation therapy.
- Author
-
Sjövall, Johanna, Chua, Benjamin, Pryor, David, Burmeister, Elizabeth, Foote, Matthew C., Panizza, Benedict, Burmeister, Bryan H., and Porceddu, Sandro V.
- Subjects
- *
POSITRON emission tomography , *HEAD & neck cancer treatment , *LYMPH nodes , *PRESERVATION of organs, tissues, etc. , *CANCER chemotherapy - Abstract
Summary Objectives The current study presents the long-term results from a study designed to evaluate a restaging positron emission tomography (PET) directed policy whereby neck dissections were omitted in all node positive head and neck squamous cell carcinoma (N + HNSCC) patients with PET-negative lymph nodes after definitive radiotherapy (RT), with or without chemotherapy. Methods A post-therapy nodal response assessment with PET and computed tomography (CT) was performed in patients who achieved a complete response at the primary site after definitive radiotherapy. Patients with PET-negative lymph nodes were observed regardless of residual CT abnormalities. Results One hundred and twelve patients, the majority of whom (83 patients, 74%) had oropharyngeal primaries, were treated on protocol. Median follow-up was 62 months. Negative and positive predictive values for the restaging PET was 97.1% and 77.8% respectively, with only one patient who was PET-negative after treatment experiencing an isolated nodal relapse. Conclusion PET-guided management of the neck following organ preservation therapy effectively spares neck dissections in patients with N + HNSCC without compromising isolated nodal control or overall survival. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
18. Stage III Melanoma in the Axilla: Patterns of Regional Recurrence After Surgery With and Without Adjuvant Radiation Therapy.
- Author
-
Pinkham, Mark B., Foote, Matthew C., Burmeister, Elizabeth, Thomas, Janine, Meakin, Janelle, Smithers, B. Mark, and Burmeister, Bryan H.
- Subjects
- *
MELANOMA , *AXILLA , *CANCER relapse , *CANCER radiotherapy , *ADJUVANT treatment of cancer , *RETROSPECTIVE studies , *MEDICAL databases - Abstract
Purpose: To describe the anatomic distribution of regionally recurrent disease in patients with stage III melanoma in the axilla after curative-intent surgery with and without adjuvant radiation therapy. Methods and Materials: A single-institution, retrospective analysis of a prospective database of 277 patients undergoing curative-intent treatment for stage III melanoma in the axilla between 1992 and 2012 was completed. For patients who received radiation therapy and those who did not, patterns of regional recurrence were analyzed, and univariate analyses were performed to assess for potential factors associated with location of recurrence. Results: There were 121 patients who received adjuvant radiation therapy because their clinicopathologic features conferred a greater risk of regional recurrence. There were 156 patients who received no radiation therapy. The overall axillary control rate was 87%. There were 37 patients with regional recurrence; 17 patients had received adjuvant radiation therapy (14%), and 20 patients (13%) had not. The likelihood of in-field nodal recurrence was significantly less in the adjuvant radiation therapy group (P=.01) and significantly greater in sites adjacent to the axilla (P=.02). Patients with high-risk clinicopathologic features who did not receive adjuvant radiation therapy also tended to experience in-field failure rather than adjacent-field failure. Conclusions: Patients who received adjuvant radiation therapy were more likely to experience recurrence in the adjacent-field regions rather than in the in-field regions. This may not simply reflect higher-risk pathology. Using this data, it may be possible to improve outcomes by reducing the number of adjacent-field recurrences after adjuvant radiation therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
19. Randomized trial of 8Gy in 1 versus 20Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05)
- Author
-
Roos, Daniel E., Turner, Sandra L., O'Brien, Peter C., Smith, Jennifer G., Spry, Nigel A., Burmeister, Bryan H., Hoskin, Peter J., and Ball, David L.
- Subjects
- *
RADIOTHERAPY , *METASTASIS , *NEUROPATHY , *MEDICAL radiology - Abstract
Abstract: Background and purpose: Despite numerous randomized trials investigating radiotherapy (RT) fractionation schedules for painful bone metastases, there are very few data on RT for bone metastases causing pain with a neuropathic component. The Trans-Tasman Radiation Oncology Group undertook a randomized trial comparing the efficacy of a single 8Gy (8/1) with 20Gy in 5 fractions (20/5) for this type of pain. Materials and methods: Eligible patients had radiological evidence of bone metastases from a known malignancy with no change in systemic therapy within 6 weeks before or anticipated within 4 weeks after RT, no other metastases along the distribution of the neuropathic pain and no clinical or radiological evidence of cord/cauda equina compression. All patients gave written informed consent. Primary endpoints were pain response within 2 months of commencement of RT and time to treatment failure (TTF). The hypothesis was that 8/1 is at least as effective as 20/5 and the planned sample size was 270 patients. Results: Between February 1996 and December 2002, 272 patients were randomized (8/1:20/5=137:135) from 15 centres (Australia 11, New Zealand 3, UK 1). The commonest primary cancers were lung (31%), prostate (29%) and breast (8%); index sites were spine (89%), rib (9%), other (2%); 72% of patients were males and the median age was 67 (range 29–89). The median overall survival (95% CI) for all randomized patients was 4.8mo (4.2–5.7mo). The intention-to-treat overall response rates (95% CI) for 8/1 vs 20/5 were 53% (45–62%) vs 61% (53–70%), P=0.18. Corresponding figures for complete response were 26% (18–34%) vs 27% (19–35%), P=0.89. The estimated median TTFs (95% CI) were 2.4mo (2.0–3.3mo) vs 3.7mo (3.1–5.9mo) respectively. The hazard ratio (95% CI) for the comparison of TTF curves was 1.35 (0.99–1.85), log-rank P=0.056. There were no statistically significant differences in the rates of re-treatment, cord compression or pathological fracture by arm. Conclusions: 8/1 was not shown to be as effective as 20/5, nor was it statistically significantly worse. Outcomes were generally poorer for 8/1, although the quantitative differences were relatively small. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
20. Quality assurance experience with the randomized neuropathic bone pain trial (Trans-Tasman Radiation Oncology Group, 96.05)
- Author
-
Roos, Daniel E., Davis, Sidney R., Turner, Sandra L., O'Brien, Peter C., Spry, Nigel A., Burmeister, Bryan H., Hoskin, Peter J., and Ball, David L.
- Subjects
- *
RADIATION , *NEUROLOGICAL disorders - Abstract
Background and purpose: Trans-Tasman Radiation Oncology Group 96.05 is a prospective randomized controlled trial comparing a single 8 Gy with 20 Gy in five fractions of radiotherapy (RT) for neuropathic pain due to bone metastases. This paper summarizes the quality assurance (QA) activities for the first 234 patients (accrual target 270).Materials and methods: Independent audits to assess compliance with eligibility/exclusion criteria and appropriateness of treatment of the index site were conducted after each cohort of approximately 45 consecutive patients. Reported serious adverse events (SAEs) in the form of cord/cauda equina compression or pathological fracture developing at the index site were investigated and presented in batches to the Independent Data Monitoring Committee. Finally, source data verification of the RT prescription page and treatment records was undertaken for each of the first 234 patients to assess compliance with the protocol.Results: Only one patient was found conclusively not to have genuine neuropathic pain, and there were no detected ‘geographical misses’ with RT fields. The overall rate of detected infringements for other eligibility criteria over five audits (225 patients) was 8% with a dramatic improvement after the first audit. There has at no stage been a statistically significant difference in SAEs by randomization arm. There was a 22% rate of RT protocol variations involving ten of the 14 contributing centres, although the rate of major dose violations (more than ±10% from protocol dose) was only 6% with no statistically significant difference by randomization arm (
P=0.44 ).Conclusions: QA auditing is an essential but time-consuming component of RT trials, including those assessing palliative endpoints. Our experience confirms that all aspects should commence soon after study activation. [Copyright &y& Elsevier]- Published
- 2003
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.